QURE News and Press, uniQure N.V. From 11/01/23

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

uniQure N.V. (QURE) is expected to report $-1.49 for Q3 2023

CSL and uniQure Win 2023 Prix Galien USA Award PR Newswire HEMGENIX ® , the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass. , Oct. 27,...

Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B Canada NewsWire CSL's HEMGENIX ® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis OTTAWA, ON ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delive...

2023-10-05 13:49:37 ET Shares of uniQure (NASDAQ: QURE) were up more than 8% as of 1 p.m. after rising as much as 14% earlier in the day. So far this year, the biotech stock is down more than 70%. The gene-editing therapy company said it plans to cut back staff and progr...

2023-10-05 07:59:37 ET More on uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure: The AMT-130 Readout uniQure cleared to start U.S. trial for gene therapy Seeking Alpha’s Quant Rating on uniQure Historical earnings data for u...

~ Reduction of 28% of workforce not related to HEMGENIX ® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments in more than half of research and technology projects, centralizing op...

2023-10-04 17:50:03 ET Gainers: Prime Medicine ( NASDAQ: PRME ) +5% . uniQure ( QURE ) +5% . Aclaris Therapeutics ( ACRS ) +4% . ALX Oncology Holdings  ( ALXO ) +3% . Aurora Innovation ( AUR ) +3% . Losers: MaxCy...

2023-09-21 14:37:34 ET More on uniQure Seeking Alpha’s Quant Rating on uniQure Historical earnings data for uniQure Financial information for uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure: The AMT-130 Readout For ...